Cargando…

Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study

AIMS: Dapagliflozin has been widely used for the treatment of type 2 diabetes mellitus (T2DM) and heart failure (HF). However, data concerning the association between dapagliflozin and the recurrence of atrial fibrillation (AF), especially in patients following Cox-Maze IV (CMIV), are rare. We aim t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Zhan, Osmanaj, Florian, Yang, Yunxiao, Hua, Kun, Yang, Xiubin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Trial Design
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655060/ https://www.ncbi.nlm.nih.gov/pubmed/37939825 http://dx.doi.org/10.1093/europace/euad333

Ejemplares similares

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Atrial fibrillation fingerprinting; spotting bio‐electrical markers to early recognize atrial fibrillation by the use of a bottom‐up approach (AFFIP): Rationale and design
por: Starreveld, Roeliene, et al.
Publicado: (2020)

Rationale and Design of the ADIDAS Study: Association Between Dapagliflozin-Induced Improvement and Anemia in Heart Failure Patients
por: Zeng, Jianping, et al.
Publicado: (2021)

Effect of Preablation Glycemic Control on Outcomes of Atrial Fibrillation Patients With Diabetes Mellitus Following Valvular Surgery Combined With the Cox-Maze IV Procedure
por: Peng, Zhan, et al.
Publicado: (2022)

Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study
por: Bunch, T. Jared, et al.
Publicado: (2019)

EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non‐valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study
por: Picard, Fabien, et al.
Publicado: (2019)

Design and Rationale of the PRAGUE‐12 Trial: A Large, Prospective, Randomized, Multicenter Trial That Compares Cardiac Surgery With Left Atrial Surgical Ablation With Cardiac Surgery Without Ablation in Patients With Coronary and/or Valvular Heart Disease Plus Atrial Fibrillation
por: Straka, Zbyněk, et al.
Publicado: (2012)

The PhysioVP-AF study, a randomized controlled trial to assess the clinical benefit of physiological ventricular pacing vs. managed ventricular pacing for persistent atrial fibrillation prevention in patients with prolonged atrioventricular conduction: design and rationale
por: Pastore, Gianni, et al.
Publicado: (2023)

Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non–vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH–AFNET 6) trial
por: Kirchhof, Paulus, et al.
Publicado: (2017)

Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the DARE‐19 study
por: Kosiborod, Mikhail, et al.
Publicado: (2021)

Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting
por: Cannon, Christopher P., et al.
Publicado: (2016)

German Cardiac Arrest Registry: rationale and design of G-CAR
por: Pöss, Janine, et al.
Publicado: (2022)

Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)–Coalition IV trial()()
por: Lopes, Renato D., et al.
Publicado: (2021)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)
por: McMurray, John J.V., et al.
Publicado: (2019)

Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease
por: Sorbets, Emmanuel, et al.
Publicado: (2017)

Rationale and design of the EPCHF trial: the early palliative care in heart failure trial (EPCHF)
por: Becher, Marc Ulrich, et al.
Publicado: (2021)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study
por: Bhatt, Deepak L., et al.
Publicado: (2019)

Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study
por: Teerlink, John R., et al.
Publicado: (2017)

Drug‐coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET‐SMALL 2
por: Gilgen, Nicole, et al.
Publicado: (2018)

Design and rationale of the North Indian ST‐Segment Elevation Myocardial Infarction Registry: A prospective cohort study
por: Arora, Sameer, et al.
Publicado: (2019)

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry
por: Pereira, Naveen L., et al.
Publicado: (2021)

Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA: Rationale and Study Design for the RIC-AFRICA Trial
por: Lukhna, Kishal, et al.
Publicado: (2021)

Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI)
por: Yndigegn, Troels, et al.
Publicado: (2022)

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study
por: Capell, Warren H., et al.
Publicado: (2021)

Prognostic Value of Short-Term Follow-up of Multiple Biomarkers After Discharge in Hospitalized Patients With Acute Heart Failure (POSTBIO-HF): Rationale and Study Design
por: Cho, Dong-Hyuk, et al.
Publicado: (2022)

Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: Rationale and design of the EARNEST study()
por: Moody, William E., et al.
Publicado: (2014)

Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry
por: Berman, Adam N., et al.
Publicado: (2020)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

Improving outcomes of AF ablation by integrated personalized lifestyle interventions: rationale and design of the prevention to improve outcomes of PVI (POP) trial
por: Vermeer, Jasper, et al.
Publicado: (2023)

Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy
por: Haghikia, Arash, et al.
Publicado: (2015)

Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial
por: Biscaglia, Simone, et al.
Publicado: (2020)

Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control (IMPACTS): Rationale and design of a cluster-randomized trial()()
por: Mills, Katherine T., et al.
Publicado: (2020)

Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial
por: Li, Yi, et al.
Publicado: (2020)

Rationale and design of a navigator‐driven remote optimization of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction
por: Blood, Alexander J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o5182eqq3lha003fupokr4dk45